Next Article in Journal
Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
Next Article in Special Issue
Pharmacokinetic Properties of the Novel Synthetic Cannabinoid 5F-APINAC and Its Influence on Metabolites Associated with Neurotransmission in Rabbit Plasma
Previous Article in Journal
Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating
Previous Article in Special Issue
Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects
Article

Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature

1
Institute of Pharmacology and Experimental Therapeutics/IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
2
Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Medical University Innsbruck, 6020 Innsbruck, Austria
3
Department of Pharmacology, University of Arkansas for Medical Sciences (Adjunct Professor), Little Rock, AR 72205, USA
4
REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, UCIBIO, University of Porto, 4050-313 Porto, Portugal
5
Center for Neuroscience and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, 3004-504 Coimbra, Portugal
6
Faculty of Medicine, Institute of Immunology, University of Coimbra, 3004-504 Coimbra, Portugal
7
Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
8
Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal
9
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal
10
Clinical Academic Center of Coimbra (CACC), 3004-504 Coimbra, Portugal
11
ESTESC-Coimbra Health School, Pharmacy, Polytechnic Institute of Coimbra, 3046-854 Coimbra, Portugal
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Antoni Camins Espuny
Pharmaceuticals 2021, 14(3), 271; https://doi.org/10.3390/ph14030271
Received: 17 February 2021 / Revised: 11 March 2021 / Accepted: 13 March 2021 / Published: 16 March 2021
3,4-Methylenedioxypyrovalerone (MDPV), a widely available synthetic cathinone, is a popular substitute for classical controlled drugs of abuse, such as methamphetamine (METH). Although MDPV poses public health risks, its neuropharmacological profile remains poorly explored. This study aimed to provide evidence on that direction. Accordingly, C57BL/6J mice were exposed to a binge MDPV or METH regimen (four intraperitoneal injections every 2 h, 10 mg/kg). Locomotor, exploratory, and emotional behavior, in addition to striatal neurotoxicity and glial signature, were assessed within 18–24 h, a known time-window encompassing classical amphetamine dopaminergic neurotoxicity. MDPV resulted in unchanged locomotor activity (open field test) and emotional behavior (elevated plus maze, splash test, tail suspension test). Additionally, striatal TH (METH neurotoxicity hallmark), Iba-1 (microglia), GFAP (astrocyte), RAGE, and TLR2/4/7 (immune modulators) protein densities remained unchanged after MDPV-exposure. Expectedly, and in sheer contrast with MDPV, METH resulted in decrease general locomotor activity paralleled by a significant striatal TH depletion, astrogliosis, and microglia arborization alterations (Sholl analysis). This comparative study newly highlights that binge MDPV-exposure comes without evident behavioral, neurochemical, and glial changes at a time-point where METH-induced striatal neurotoxicity is clearly evident. Nevertheless, neuropharmacological MDPV signature needs further profiling at different time-points, regimens, and brain regions. View Full-Text
Keywords: 3,4-methylenedioxypyrovalerone; methamphetamine; behavior; glia 3,4-methylenedioxypyrovalerone; methamphetamine; behavior; glia
Show Figures

Figure 1

MDPI and ACS Style

Campeão, M.; Fernandes, L.; Pita, I.R.; Lemos, C.; Ali, S.F.; Carvalho, F.; Rodrigues-Santos, P.; Fontes-Ribeiro, C.A.; Soares, E.; Viana, S.D.; Pereira, F.C. Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature. Pharmaceuticals 2021, 14, 271. https://doi.org/10.3390/ph14030271

AMA Style

Campeão M, Fernandes L, Pita IR, Lemos C, Ali SF, Carvalho F, Rodrigues-Santos P, Fontes-Ribeiro CA, Soares E, Viana SD, Pereira FC. Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature. Pharmaceuticals. 2021; 14(3):271. https://doi.org/10.3390/ph14030271

Chicago/Turabian Style

Campeão, Mafalda, Luciana Fernandes, Inês R. Pita, Cristina Lemos, Syed F. Ali, Félix Carvalho, Paulo Rodrigues-Santos, Carlos A. Fontes-Ribeiro, Edna Soares, Sofia D. Viana, and Frederico C. Pereira 2021. "Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature" Pharmaceuticals 14, no. 3: 271. https://doi.org/10.3390/ph14030271

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop